These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38561370)

  • 21. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
    Trefond L; Lhote R; Mathian A; de Chambrun MP; Pha M; Hie M; Miyara M; Papo M; Moyon Q; Taieb D; Saade S; Salem TB; Haroche J; Chasset F; Aubart FC; Zahr N; Amoura Z
    Semin Arthritis Rheum; 2024 Jun; 66():152417. PubMed ID: 38394986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
    Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
    Takamasu E; Yokogawa N; Shimada K; Sugii S
    Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
    Petri M; Konig MF; Li J; Goldman DW
    Arthritis Rheumatol; 2021 Jun; 73(6):997-1004. PubMed ID: 33403833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.
    Telek HH; Yesilirmak N; Sungur G; Ozdemir Y; Yesil NK; Ornek F
    Doc Ophthalmol; 2017 Dec; 135(3):187-194. PubMed ID: 28852896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus.
    Lee JE; Nam DR; Sung YK; Kim YJ; Jung SY
    Sci Rep; 2023 May; 13(1):7270. PubMed ID: 37142639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
    Ameen Ismail A; Sadek SH; Hatata RM
    BMC Ophthalmol; 2022 Nov; 22(1):434. PubMed ID: 36376841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous.
    Zamani B; Hasan-Abad AM; Rafizadeh SM; Akbari H; Motedayyen H
    J Immunoassay Immunochem; 2024 May; 45(3):178-188. PubMed ID: 38722204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.
    Nishiyama T; Kondo Y; Tsuboi H; Noma H; Tabuchi D; Sugita T; Okamoto S; Terasaki T; Shimizu M; Honda F; Ohyama A; Kurata I; Yagishita M; Abe S; Takahashi H; Osada A; Hagiwara S; Matsumoto I; Sumida T
    Mod Rheumatol; 2021 Nov; 31(6):1107-1112. PubMed ID: 33496215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
    Garg S; Unnithan R; Hansen KE; Costedoat-Chalumeau N; Bartels CM
    Arthritis Care Res (Hoboken); 2021 May; 73(5):707-716. PubMed ID: 32004406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macular and peripapillary vessel density alterations in a large series of patients with systemic lupus erythematosus without ocular involvement.
    Subasi S; Kucuk KD; San S; Cefle A; Tokuc EO; Balci S; Yazici A
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3543-3552. PubMed ID: 35792929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.
    Jallouli M; Galicier L; Zahr N; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Le Thi Huong D; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Leroux G; Cohen-Bittan J; Sellam J; Mariette X; Blanchet B; Hulot JS; Amoura Z; Piette JC; Costedoat-Chalumeau N;
    Arthritis Rheumatol; 2015 May; 67(8):2176-84. PubMed ID: 25989906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
    Carmichael SJ; Day RO; Tett SE
    Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual Impact of Early Hydroxychloroquine-Related Retinal Structural Changes in Patients with Systemic Lupus Erythematosus.
    Sallam MA; Beltagi AS; Abdellatif MA; Awadalla MA
    Ophthalmologica; 2021; 244(4):301-308. PubMed ID: 34015786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.
    Esteve-Valverde E; Tapiz-Reula A; Ruiz D; Alijotas-Reig J
    Rheumatol Int; 2020 May; 40(5):777-783. PubMed ID: 31865445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.